help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanze, M.
Right arrow Articles by Garabedian, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanze, M.
Right arrow Articles by Garabedian, M.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 9 2971-2977
Copyright © 1997 by The Endocrine Society


Original Studies

Procollagen Propeptide and Pyridinium Cross-Links as Markers of Type I Collagen Turnover: Sex- and Age-Related Changes in Healthy Children1

M. Zanze, J. C. Souberbielle, C. Kindermans, C. Rossignol and M. Garabedian

CNRS URA 583, Université Paris V, Hôpital St. Vincent de Paul (M.Z, M.G.), 75014 Paris; France Laboratoire d’Explorations Fonctionnelles, Hôpital Necker-Enfants Malades (J.C.S., C.K.), 75015 Paris; and Centre des Bilans de Santé de l’Enfant de Paris (C.R.), 75011 Paris, France

Address all correspondence and requests for reprints to: Dr. Michèle Garabédian, CNRS URA 583, Hôpital Saint Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, France.


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
The correlations among age, gender, body size parameters, and type I collagen metabolism were evaluated in 183 healthy infants, aged 8.5–27.5 months. Collagen formation was assessed by measuring serum type I collagen carboxy-terminal propeptide, and degradation was determined by urinary pyridinoline and deoxypyridinoline (measured by high performance liquid chromatography) and cross-linked N- and C-terminal telopeptides of type I collagen (measured by NTx and CrossLaps assays). A new RIA specific for deoxypyridinoline was also evaluated. The results provide reference values at 10 months and 2 yr of age, including cross-linked C-terminal telopeptides (1492 ± 685 and 1510 ± 446 in boys; 1705 ± 612 and 1849 ± 611 µg/mmol creatinine in girls; mean ± 1 SD). There was a good correlation between the high performance liquid chromatography and RIA data for deoxypyridinoline, showing that the RIA method is suitable for use in healthy children. Some correlations were found among peptide-bound cross-links, serum type I collagen carboxy-terminal propeptide, and the anthropometric parameters, suggesting that these peptides reflect bone resorption and also overall body type I collagen. Finally, there were age- and sex-related differences in the urinary excretion of the collagen degradation markers, suggesting that, unlike boys, girls maintain a high degree of collagen degradation up to the age of 24 months despite a decrease in their rate of collagen formation.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
THE METABOLISM of type I collagen is of considerable interest as an indicator of bone turnover (1). The concentration of the carboxy-terminal propeptide of type I collagen (PICP) in serum is used as a marker of bone formation. The serum PICP concentration in growing children undergoes age-related changes and is significantly greater than that in adults. Serum PICP is also correlated with height velocity in healthy children and after GH therapy in children with GH deficiency (2, 3, 4).

On the other hand, the fragments formed by the breakdown of type I collagen have provided several indicators of bone resorption (1). Newly synthesized collagen fibrils are stabilized by intermolecular cross-links. The serum cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) varies in much the same way as serum PICP in growing children (4). However, serum ICTP is not considered to be a fully sensitive marker for assessing bone resorption in adults (5). The mature cross-links can also be measured directly in urine. These cross-links are trivalent cyclic pyridinium structures: pyridinoline (Pyr), also known as hydroxylysyl pyridinoline, and deoxypyridinoline (DPyr), also known as lysyl pyridinoline (6). The total excretion of Pyr (T Pyr) and DPyr (T DPyr) is commonly measured (after hydrolysis) by high performance liquid chromatography (HPLC). In healthy children (7, 8) their concentrations are expressed relative to urinary creatinine (T Pyr/Cr and T DPyr/Cr), and these ratios vary in the same way as serum PICP and ICTP. T Pyr and T DPyr levels are low in malnourished children and increase after recovery, with a significant correlation between the subsequent concentration and height gain (9). As pyridinoline cross-links in the urine are in both free and oligopeptide-bound forms, with one kind of peptide at each end of the collagen molecule (10), immunoassays have been performed to measure both the collagen type I cross-linked N-telopeptides (NTx) (11), and C-telopeptides (CrossLaps) (12). Urinary NTx levels decrease with age between infancy and adulthood (11, 13), but no information is available concerning CrossLaps during childhood.

We have studied 183 healthy infants divided into two groups according to age to 1) provide reference values for several available urinary markers of collagen degradation, including CrossLaps for infants according to age and sex; 2) examine the relationships among the various indicators of bone collagen degradation used [T Pyr and T DPyr measured by HPLC, NTx, and CrossLaps; free DPyr (F DPyr) and T DPyr measured by a recently developed RIA]; and 3) investigate the relationships between bone collagen formation and degradation in early childhood and assess the age-related and gender-related variations in these processes.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Subjects

The subjects were seen in June and July 1995 at the Centre de Bilans de Santé de l’Enfant of Paris. A total of 183 healthy Caucasian children who were having an annual checkup were included. The present study was carried out on the remaining urine and serum samples. The recorded parameters were gender, age, weight, height, and dietary intake. Breast-fed children were excluded to eliminate interferences linked to the effect of breast-feeding on calcium and phosphorus metabolism. The body size parameters were measured by the nursing staff with standard procedures, including weight (kilograms) and height (centimeters), which were used to calculate body mass index (BMI) or Quetelet index as weight over the square of height. Body surface area (square meters) was obtained from the equation validated in children (14). To avoid circadian variations, all samples were taken at the same time of days, between 0800–1100 h in the morning. The children were assigned to one of three groups: 1) 10-month-old children seen after breakfast (mean age ± 1 SD, 6.3 ± 0.78 months; range, 8.5–13 months; n = 66); 2) 24-month-old children seen after breakfast (mean age ± 1 SD, 22.9 ± 1.33 months; range, 21–27.5 months; n = 49); and 3) 24-month-old children seen before breakfast (fasting group; mean age ± 1 SD, 23.3 ± 1.12 months; range, 21–27.5 months; n = 68).

Urine samples were assayed for Cr, calcium, and phosphorus. The samples were then stored at -20 C until the collagen parameters were measured.

The remainders of the serum samples were assayed for protein and total calcium before being stored at -20 C for PICP measurement.

Biochemical analysis

Serum assays. Serum protein and total calcium were measured by routine laboratory methods, and calcium was corrected for protein according to the formula of Parfitt. The values are expressed as millimoles per L. Serum concentrations of PICP were measured using an equilibrium RIA (15), and results are expressed as micrograms per L.

Urinary assays. Urinary Cr (U Cr) and calcium (U Ca) were measured by an automated chemistry analyzer (Beckman Synchron CX system, Beckman Instruments, Brea, CA). Phosphorus was measured with a Technicon colorimetric method (Bayer Diagnostics, France). The results for U Ca and phosphorus are expressed as millimoles per mmol Cr excreted.

T Pyr and T DPyr measurements by HPLC

Urine samples were diluted with equal volumes of pyrogen-free water before measurement according to a previously described method (16). Briefly, the cross-links were extracted from the acid-hydrolyzed samples by cellulose chromatography and separated by HPLC on a reverse phase C18 column with fluorescence detection. The standards of Pyr and DPyr were prepared from human bone according to the method of Eyre (17). The interassay variations were 6.5% for T Pyr and 10.9% for T DPyr. Urinary concentrations are expressed as nanomoles per mmol Cr.

F DPyr and T DPyr RIA

Samples were analyzed by a new RIA (Pyrilinks-D RIA, Metra Biosystems, Mountain View, CA) for F DPyr and T DPyr. The Pyrilinks-D RIA is a competitive RIA that uses a monoclonal anti-DPyr antibody (purified murine monoclonal anti-DPyr antibody) coated on the inner surface of polystyrene tubes. This antibody is the same as that used in the previously validated enzyme-linked immunosorbent assay (ELISA) for urinary deoxypyridinoline (18). DPyr in the sample competes with 125I-labeled DPyr for the antibody. The incubated tubes were washed to remove unbound [125I]DPyr and then counted. Pyrilinks-D reacts less than 1% with free pyridinoline. The sensitivity determined as 2 SD at zero standard was 2 nmol/L. When spiking 40 nmol/L DPyr in three urine samples containing 11.5, 33.4, and 64.4 nmol/L endogenous DPyr, the recoveries ranged from 90–100%. The intraassay (n = 18) and interassay (n = 37) coefficients of variation assessed in three samples with different concentrations were less than 6% and 8%, respectively.

F DPyr assay. Samples, standards, and controls (50 µL) were diluted in 450 µL wash buffer; 100 µL diluted standards, controls, and samples were dispensed in duplicate in the coated tubes, followed by 200 µL cold (2–8 C) [125I]DPyr. Two additional tubes were included for total counts. The tubes were gently vortexed and left in the dark at 2–8 C for 2 h. The supernatants were then discarded, and 4 mL cold (2–8 C) wash buffer were placed in each tube except those for the total counts. The tubes were decanted, and supernatants were discarded. The [125I]DPyr bound was counted in a suitable {gamma}-counter and quantified by comparison with the standard curve obtained with purified bovine bone DPyr in 10 mmol/L phosphoric acid. All values are expressed as nanomoles per mmol Cr.

T DPyr assay. Urine samples were hydrolyzed before analysis as recommended by the manufacturer. Each urine sample (200 µL) was boiled in an equal volume of 6 N HCl and heated at 110 C for 18 h in screw-capped glass tubes. Hydrolyzed samples were neutralized by adding 50 µL hydrolysate to 200 µL 1 N NaOH. The neutralized hydrolysate (50 µL) was diluted in 450 µL assay buffer. The following steps were the same as those for F DPyr measurement. Results for the hydrolyzed samples were multiplied by 10 to obtain T DPyr concentrations and expressed as nanomoles per mmol Cr.

CrossLaps. CrossLaps was measured by ELISA (CrossLaps ELISA, Osteometer, Rodovre, Denmark). This assay uses a polyclonal antiserum raised against an immobilized synthetic peptide with an amino acid sequence (EKAHDGGR) specific for part of the C-telopeptide of the {alpha}1(I) collagen chain (12). Results are expressed as micrograms per mmol Cr.

NTx. NTx was measured by ELISA (Osteomark, Ostex International, Seattle, WA) (11). The results are expressed as nanomoles of bone collagen equivalents per mmol Cr.

Calculated parameters

The free fraction of deoxypyridinoline (F DPyr/T DPyr) and the ratio of T Pyr to T DPyr (Pyr/DPyr) in urine were calculated. The peptide-bound DPyr, (B DPyr) was estimated as T DPyr minus F DPyr and expressed as nanomoles per mmol Cr.

Statistical analysis

All results are expressed as the mean ± 1 SD, except when indicated. Comparisons between groups were assessed by Student’s t test for unpaired data. Variables not known to be Gaussian distributed (BMI, body surface area, serum PICP, and all urinary parameters) underwent logarithmic (ln) transformation before using Student’s t test. Relationships between parameters were assessed by Spearman’s rank correlation. P < 0.05 was significant.


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Body size and laboratory characteristics

The values for body size parameters are given in Table 1Go. Boys had greater weight, height, and body surface area than girls at 10 and 24 months of age. Before further biological analysis, the effect of fasting was tested on parameters of calcium metabolism and on CrossLaps excretion in 117 children seen at 24 months of age. Fasting had no effect on the serum and urine parameters (Table 2Go). The data obtained for all 24-month-old children were, therefore, pooled before analysis according to gender and comparison to 10-month-old children.


View this table:
[in this window]
[in a new window]
 
Table 1. Mean ± 1 SD of body size parameters in 183 children

 

View this table:
[in this window]
[in a new window]
 
Table 2. Influence of fasting on biological parameters in 24-month-old children

 
Children aged 24 months had significantly lower serum corrected calcium levels than those 10 months of age (Table 3Go). Analysis of their spot urine samples showed higher creatinine concentration in both sexes, lower phosphorus/Cr ratios in boys, and higher U Ca/Cr ratios in girls compared to corresponding values in the 10-month-old children. For the same age, gender had no clear effect on these parameters.


View this table:
[in this window]
[in a new window]
 
Table 3. Mean ± 1 SD concentrations of calcium metabolism parameters in 183 children

 
Relationships between several urinary markers of collagen metabolism

Urine samples from 38 infants, aged 10 months, were assayed by HPLC for T Pyr and T DPyr. Expressed as ratios of Cr, the T Pyr and T DPyr values measured by HPLC were highly correlated (r = 0.91; P = 0.0001; Fig. 1aGo). Results were compared to those obtained by assaying the same samples for CrossLaps by ELISA, for NTx by ELISA, and for F DPyr and T DPyr using a recently developed RIA. As ratios of Cr, T DPyr measured by the reference HPLC method was closely correlated (P = 0.0001) with F DPyr (r = 0.82) and T DPyr (r = 0.80) measured by RIA as well as with CrossLaps (r = 0.72; Fig. 1Go, b, c, and d). It was less tightly correlated with NTx (r = 0.53; P = 0.004; Fig. 1eGo).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 1. Correlation between the urinary concentrations of T DPyr measured by HPLC and T Pyr (HPLC; a), F DPyr (RIA; b), T DPyr (RIA; c), CrossLaps (ELISA; d), and NTx (ELISA; e).

 
Age-related changes in collagen markers

The serum PICP concentrations of both boys and girls were significantly lower at 24 months than at 10 months of age (Table 4Go). When each of the age groups was considered separately, there was an inverse correlation between age and serum PICP concentration in the boys aged 10 months (r = -0.53; P = 0.02), but not in the older boys or in the girls. Like serum PICP, urinary F DPyr/Cr, T DPyr/Cr, and NTx/Cr levels were significantly lower at 24 months than at 10 months of age in boys. In contrast, CrossLaps/Cr did not change in boys with increasing age, and none of the tested urinary markers of collagen degradation showed age-related changes in girls.


View this table:
[in this window]
[in a new window]
 
Table 4. Mean ± 1 SD concentrations of collagen metabolism indicators in 183 children

 
Gender-related changes in collagen markers

None of the parameters analyzed in children aged 10 months differed between boys and girls (Table 4Go). The serum PICP levels and the urinary F DPyr/T DPyr ratios of boys and girls aged 24 months were also the same, but the 24-month-old girls had significantly higher values than boys for urinary F DPyr/Cr, T DPyr/Cr, B DPyr/Cr, CrossLaps/Cr, and NTx/Cr (Table 4Go).

Relationships between markers of collagen formation and degradation

Serum PICP did not correlate with T Pyr/Cr, T DPyr/Cr measured by HPLC or RIA, F DPyr/Cr, or B DPyr/Cr in any group. In contrast, correlations were found between serum PICP and CrossLaps/Cr levels in the 10-month-old boys (r = 0.70; P = 0.048) and between serum PICP and NTx/Cr ratios in the 24-month-old girls (r = 0.57; P = 0.021).

Relationships between collagen markers and body size parameters

For all subjects, the serum PICP concentration showed a significant negative correlation with weight, height, body surface area, and BMI, but this correlation was not found within the groups of infants separated according to age (Fig. 2Go). Only the girls aged 24 months showed a significant positive correlation between BMI and serum PICP (r = 0.51; P = 0.041).



View larger version (21K):
[in this window]
[in a new window]
 
Figure 2. Relationship between height and serum PICP concentration in children aged 10 months ({circ}) and 24 months (+).

 
There was some relationship between urinary markers of collagen degradation and body size parameters, but it differed with age and sex. No relationship was found between body size parameters and F DPyr/Cr or T DPyr/Cr (HPLC or RIA) in boys regardless of age, or in girls aged 24 months. However, F DPyr/Cr positively correlated with height (r = 0.47; P = 0.036), and its correlation with body surface area was at borderline significance (r = 0.43; P = 0.054) in girls aged 10 months. No relationship was found between NTx/Cr and body size parameters, except for a positive correlation with BMI (r = 0.59; P = 0.012) and a borderline correlation with weight (r = 0.46; P = 0.053) in the 24-month-old girls. Correlations between CrossLaps/Cr and body size parameters were found only in the 24-month-old boys (with weight, r = -0.28; P = 0.023; with BMI, r = -0.24; P = 0.049; with body surface area, r = -0.28; P = 0.023).


    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Infancy is associated with the highest rate of skeletal growth and intense bone-modeling activity. It is thus a period of particular interest for the study of type I collagen metabolism. The 183 healthy infants we studied all had high levels of serum PICP. The values were 2- to 3-fold higher than those of healthy adolescents (3, 4). The serum PICP concentration also significantly decreased between 8–13 and 21- 27 months, suggesting a link between this age-related decrease and the slowing of growth. Other investigators have attempted to correlate serum PICP with infant height or weight (2) or with growth rate shortly before or after blood sampling (19). However, pooling the data from growing children of different maturational stages may lead to associations that obviously disappear when only samples from children of the same age are used. In the present cohort, serum PICP was negatively correlated with height and weight when the values for all children were pooled, but not when the children were separated into age groups. Yet, there was a positive correlation between serum PICP and BMI in the 2-yr-old girls, suggesting that serum PICP reflects not only bone growth, but also the overall somatic growth of infants. In contrast to one report (19), we found no significant gender-related difference in serum PICP values despite a trend for greater concentrations in boys.

Similar to serum PICP, several urinary indicators of bone resorption have been shown to be very high during infancy and to decrease with age. This was shown for T Pyr/Cr and T DPyr/Cr (7, 8, 20, 21, 22) and for NTx/Cr (11, 13) in mixed populations of boys and girls. The results of the present survey also show high values of T Pyr/Cr, T DPyr/Cr, F DPyr/Cr, and NTx/Cr in infants. The proportion of F DPyr was similar to that in healthy children (23) and adults (24), but lower than that in adolescents (24). High values for T DPyr were found with both the HPLC assay and the newly developed RIA assay that uses the monoclonal antibody developed for F DPyr measurement by ELISA (18). Close correlations between the RIA values for F DPyr and T DPyr and the HPLC values for T DPyr suggest that this RIA is a suitable method to assay DPyr in urine. The present results also show an age-related decrease in the urinary excretion of these markers in boys between 10–24 months of age, but there was no age-related decrease in girls. Another marker of type I collagen degradation, urinary CrossLaps/Cr, was analyzed. No information is yet available on this marker during childhood. Like the other markers, high levels of CrossLaps/Cr were found in infants; they were 5- to 7-fold higher than those in healthy premenopausal women (25, 26). However, this marker differed from NTx and other cross-links as it showed no age-related decrease during the first 2 yr of life.

It is difficult to interpret urinary data from young children. Spot urine samples are usually preferred to 24-h samples because it is not easy to collect urine for long periods of time. Cross-links excretion does not appear to be directly influenced by renal function in infancy (21), and the assessment of collagen degradation products based on their concentration relative to creatinine excretion in first void urine samples is considered to be valid in healthy children (8). However, the urinary excretion of creatinine depends on protein intake and skeletal muscle mass, which is closely related to growth. Thus, identical values at 10 and 24 months of age, as is the case for T DPyr/Cr and NTx/Cr in females and for CrossLaps/Cr in both sexes, may, in fact, reflect an increase in the absolute excretion of these degradation products with increasing age, as urinary Cr increases during this period. Alternatively, part of the decrease observed in T DPyr/Cr and NTx/Cr in boys results from the increase in urinary Cr, and the absolute decrease in the degradation of collagen may thus be smaller than that in their ratio to Cr.

Nevertheless, comparative analysis of the data obtained with different markers of collagen degradation show clear differences among these markers. First, there was no correlation between serum PICP and T Pyr/Cr, T DPyr/Cr, or F DPyr/Cr in any of the four groups of infants when analyzed separated according to age and sex, unlike the situation in adolescents (27). However, serum PICP correlated with urinary CrossLaps/Cr in boys aged 10 months and with NTx/Cr in girls aged 24 months. These relationships suggest that urinary CrossLaps and NTx excretions may partly reflect the rate of collagen production during rapid growth. In agreement with this hypothesis, antibodies to NTx and CrossLaps are thought to react with all type I collagen peptides rather than only with bone-derived ones (28). Second, CrossLaps/Cr did not decrease during the first 2 yr of life, unlike the other markers of collagen degradation. This suggests differences in production of the various cross-links during early childhood, presumably linked to differences in maturation of the enzymatic systems involved.

The simultaneous analysis of the changes in collagen synthesis and degradation markers also shows sex-linked differences and a certain degree of uncoupling of the two processes during early infancy. Gender did not appear to influence collagen metabolism in the 10-month-old infants. It also did not influence PICP levels in the 24-month-old children. However, levels of all degradation markers were significantly higher in girls than in boys at this age. Moreover, the parallel decreases in serum PICP and urinary degradation markers observed in boys between 10–24 months of age did not occur in girls. Thus, unlike the boys, the girls appear to maintain a high degree of collagen degradation up to the age of 24 months despite a decrease in their rate of collagen formation. The lack of a close link between type I collagen formation and degradation is not surprising because of the different regulatory systems involved in the control of skeletal growth, bone modeling, and bone remodeling. Urinary excretion of T DPyr and, to a lesser extent, of T Pyr is considered to reflect bone resorption in adults. If one assumes that this is also the case during infancy, the present results suggest that the timing of the changes in the resorption rate of the skeleton during the first 2 yr of life differ with the sex. However, as mentioned above, urinary excretion of the cross-links may not reflect bone resorption alone in rapidly growing children and may in part be dependent on overall somatic growth. Earlier studies in healthy children found no correlation between body size parameters and pyridinoline cross-links (29), but F DPyr/Cr showed some correlation with height at 10 months of age, and CrossLaps/Cr and NTx/Cr showed some correlations with weight, BMI, and body surface area at 24 months of age. Thus, the gender-related differences in urinary degradation markers may reflect differences in the production of the collagen degradation markers by skeletal and nonskeletal cells.

In conclusion, the present cross-sectional study provides reference values for markers of collagen metabolism during infancy, including CrossLaps. They show the potential usefulness of a newly developed RIA for measuring F DPyr and T DPyr in healthy children, which is more convenient than the time-consuming HPLC method. They show differences in the excretions of the various collagen degradation indicators and suggest that some of these indicators, especially urinary CrossLaps and NTx, commonly referred to as markers of bone resorption, may, in fact, reflect the overall type I collagen turnover during early childhood. Finally, they show gender-related differences in the metabolism of type I collagen as early as 2 yr of age.


    Acknowledgments
 
We gratefully acknowledge CIS Bio International (Gif-Sur-Yvette, France), Ortho Clinical Diagnostics (Roissy, France), and Behring Diagnostics (Rueil-Malmaison, France) for providing kits for CrossLaps, NTx, and Pyrilinks-D RIAs, respectively. We are grateful to Pierre Frotte, Philippe Bonnet, and Patricia Herviaux for their excellent assistance.


    Footnotes
 
1 This work was supported in part by a grant from Direction de la Recherche Clinique (Contract 912017; Assistance Publique Hôpitaux de Paris). Back

Received February 26, 1997.

Revised May 19, 1997.

Accepted May 27, 1997.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Calvo MS, Eyre DR, Gundberg CM. 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 17:333–368.[Abstract]
  2. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CGD, Mowat AP. 1991 Serum concentrations of type 1 and 3 procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res. 30:276–280.[Medline]
  3. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G. 1992 Serum levels of carboxyterminal propeptide of type 1 procollagen in healthy chilren from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr. 151:764–768.[CrossRef][Medline]
  4. Kubo T, Tanaka H, Inoue M, Kanzaki S, Seino Y. 1995 Serum levels of carboxyterminal propeptide of type 1 procollagen and pyridinoline crosslinked telopeptide of type 1 collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Bone. 17:397–401.[Medline]
  5. Blumsohn A, Naylor KE, Assiri AMA, Eastell R. 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem. 41:1592–1598.[Abstract/Free Full Text]
  6. Eyre DR. 1984 Cross-linking in collagen and elastin. Annu Rev Biochem. 53:717–748.[CrossRef][Medline]
  7. Rauch F, Schönau E, Woitge H, Remer T, Seibel M. 1994 Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol. 102:94–97.[Medline]
  8. Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y. 1995 Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metab. 80:1922–1928.[Abstract]
  9. Branca F, Robins SP, Ferro-Luzzi A, Golden MHN. 1992 Bone turnover in malnourished children. Lancet. 340:1493–1496.[CrossRef][Medline]
  10. Eyre DR, Ericsson L, Simon L, Krane S. 1988 Identification of urinary peptides derived from cross-linking sites in bone collagen in Paget’s disease. J Bone Miner Res. 3(Suppl 1):S210.
  11. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantification of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 7:1251–1258.[Medline]
  12. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. 1994 Immunoassay for quantifying type 1 collagen degradation products in urine evaluated. Clin Chem. 40:2022–2025.[Abstract]
  13. Bollen AM, Eyre DR. 1994 Bone resorption rates in children monitored by the urinary assay of collagen type 1 cross-linked peptides. Bone. 15:31–34.[Medline]
  14. Haycock GB, Chir B, Schwartz GJ, Wisotsky DH. 1978 Geometric method for measuring body surface area: a height-weight formula validated in infants, children and adults. J Pediatr. 93:62–66.[Medline]
  15. Melkko J, Niemi S, Risteli L, Risteli J. 1990 Radioimmunoassay of the carboxyterminal propeptide of human type 1 procollagen. Clin Chem. 36:1328–1332.[Abstract/Free Full Text]
  16. Kamel S, Brazier M. 1992 High-performance liquid chromatographic determination of 3-hydroxypyridinium derivatives as new markers of bone resorption. J Chromatogr. 574:255–260.[Medline]
  17. Eyre DR. 1987 Collagen cross-linking amino-acids. In: Cunningham LW, ed. Methods in enzymology. New York: Academic Press; 115–139.
  18. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. 1994 Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 9:1643–1649.[Medline]
  19. Lieuw-A-Fa M, Sierra RI, Specker BL. 1995 Carboxy-terminal propeptide of human type 1 collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res. 10:849–853.[Medline]
  20. Beadsworth LJ, Eyre DR, Dickson IR. 1990 Changes with age in the urinary excretion of lysyl-and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res. 5:671–676.[Medline]
  21. Tsukahara H, Miura M, Hori C, et al. 1996 Urinary excretion of pyridinium cross-links of collagen in infancy. Metabolism. 45:510–514.[CrossRef][Medline]
  22. Açil Y, Brinckmann J, Notbohm H, Müller PK, Bätge B. 1996 Changes with age in the urinary excretion of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). Scand J Clin Lab Invest. 56:275–283.[Medline]
  23. Robins SP. 1994 Biochemical markers for assessing skeletal growth. Eur J Clin Nutr. 48(Suppl 1):S199–S209.
  24. Kamel S, Brazier M, Neri V, et al. 1995 Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immumoassay methods. J Bone Miner Res. 10:1385–1392.[Medline]
  25. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res. 10:641–649.[Medline]
  26. Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C. 1996 High bone turnover is associated with low bone mass in both pre- and postmenopausal women. Bone. 19:291–298.[Medline]
  27. Blumsohn A, Hannon RA, Wrate R, et al. 1994 Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf). 40:663–670.[Medline]
  28. Robins SP. 1995 Collagen crosslinks in metabolic bone disease. Acta Orthop Scand. 66(Suppl 266):171–175.
  29. Shaw NJ, Dutton J, Fraser WD, Smith CS. 1995 Urinary pyridinoline and deoxypyridinoline excretion in children. Clin Endocrinol (Oxf). 42:607–612.[Medline]



This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
J. Leger, I. Mercat, C. Alberti, D. Chevenne, P. Armoogum, J. Tichet, and P. Czernichow
The relationship between the GH/IGF-I axis and serum markers of bone turnover metabolism in healthy children
Eur. J. Endocrinol., November 1, 2007; 157(5): 685 - 692.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Rauchenzauner, A. Schmid, P. Heinz-Erian, K. Kapelari, G. Falkensammer, A. Griesmacher, G. Finkenstedt, and W. Hogler
Sex- and Age-Specific Reference Curves for Serum Markers of Bone Turnover in Healthy Children from 2 Months to 18 Years
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 443 - 449.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanze, M.
Right arrow Articles by Garabedian, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanze, M.
Right arrow Articles by Garabedian, M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals